Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice
Open Access
- 1 June 2011
- journal article
- laboratory investigations
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 39 (6), 1439-1447
- https://doi.org/10.1097/ccm.0b013e3182120691
Abstract
Objective: W1-mAb is a chimpanzee-derived monoclonal antibody to protective antigen that improved survival when administered before anthrax lethal toxin challenge in rats. To better define W1-mAb's efficacy for anthrax, we administered it after initiation of 24-hr infusions of edema toxin and lethal toxin either alone or together in rats or following anthrax spore challenge in mice. Interventions: W1-mAb or placebo treatment. Methods and Main Results: In toxin-challenged rats treated with placebo, survival rates were lower with edema toxin (500 μg/kg) compared to lethal toxin either alone (175 μg/kg) or with edema toxin (175 μg/kg each) (8%, 33%, and 32%, respectively), but the median time to death was longer (36, 11, and 9 hrs, respectively) (p ≤ .01 for all comparisons). W1-mAb administered up to 12 hrs after edema toxin and 6 hrs after lethal toxin increased survival and reduced hypotension (p ≤ .01). However, only administration of W1-mAb at 0 hrs improved these variables with lethal toxin and edema toxin together (p ≤ .0002). In C57BL/6J mice challenged with anthrax spores subcutaneously, compared to placebo treatment (0 of 15 animals survived), W1-mAb administered beginning 24 hrs after challenge increased survival (13 of 15 survived) (p ≤ .0001). Conclusion: While rapidity of lethality may influence the effectiveness of delayed W1-mAb treatment, these rat and mouse studies provide a basis for further exploring this agent's usefulness for anthrax.Keywords
This publication has 30 references indexed in Scilit:
- Anthrax Lethal and Edema Toxins Produce Different Patterns of Cardiovascular and Renal Dysfunction and Synergistically Decrease Survival in CaninesThe Journal of Infectious Diseases, 2010
- Novel Chimpanzee/Human Monoclonal Antibodies That Neutralize Anthrax Lethal Factor, and Evidence for Possible Synergy with Anti-Protective Antigen AntibodyInfection and Immunity, 2009
- The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS)PLoS Pathogens, 2009
- Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivoProceedings of the National Academy of Sciences, 2007
- Efficient Neutralization of Anthrax Toxin by Chimpanzee Monoclonal Antibodies against Protective AntigenThe Journal of Infectious Diseases, 2006
- Genome Engineering in Bacillus anthracis Using Cre RecombinaseInfection and Immunity, 2006
- Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United StatesEmerging Infectious Diseases, 2001
- Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinaseJournal of Applied Microbiology, 1999
- Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured MacrophagesBiochemical and Biophysical Research Communications, 1998